Nasopharyngeal Carcinoma with Bone Marrow Metastasis: Positive Response to Weekly Paclitaxel Chemotherapy

Miyaushiro, Sae; Kitanaka, Akira; Kubuki, Yoko; Hidaka, Tomonori; Shide, Kotaro; Kameda, Takuro; Sekine, Masaaki; Kamiunten, Ayako; Umekita, Yoshiko; Kawabata, Takayuki; Ishiguro, Yoriko; Shimoda, Kazuya

doi:10.2169/internalmedicine.54.3917

Cited by 6 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Paclitaxel is an anti-cancer chemotherapeutic that stabilizes polymerized microtubules in metaphase, preventing the progression to anaphase in rapidly dividing cells (Schiff and Horwitz, 1980; Risinger et al ., 2014). It is one of the most commonly administered and effective chemotherapeutics in the United States and throughout the world, and it has been used to improve survival in patients with nasopharyngeal (Miyaushiro et al ., 2015), non-small cell lung (Langer et al ., 2015), breast (Sparano et al ., 2008), and ovarian cancers (Suh et al ., 2013). Clinical use of paclitaxel is limited by adverse effects that include emesis, alopecia, and diarrhea, but these effects typically resolve with cessation of treatment (Reeves et al ., 2012).…”

Section: Introductionmentioning

confidence: 99%

Lack of paclitaxel effects on intracranial self-stimulation in male and female rats: comparison to mechanical sensitivity

Legakis

Bigbee

Negus

2018

Behavioural Pharmacology

View full text Add to dashboard Cite

Paclitaxel is a cancer chemotherapy with adverse effects that include peripheral neuropathy, neuropathic pain, and depression of behavior and mood. In rodents, hypersensitive paw-withdrawal reflexes from mechanical stimuli serve as one common measure of paclitaxel-induced pain-related behavior. This study tested the hypothesis that paclitaxel would also depress rates of positively reinforced operant responding as a measure of pain-related behavioral depression. Male and female Sprague-Dawley rats were equipped with electrodes targeting the medial forebrain bundle, trained to lever press for electrical brain stimulation in an assay of intracranial self-stimulation (ICSS), and treated with four injections of varying paclitaxel doses (0.67, 2.0, or 6.0 mg/kg/injection×4 injections on alternate days). Mechanical sensitivity, body weight, and ICSS were evaluated before, during, and for 3 weeks after paclitaxel treatment. Paclitaxel doses sufficient to produce mechanical hypersensitivity did not reliably depress ICSS in male or female rats. Moreover, the degree of behavioral suppression in individual rats did not correlate with mechanical sensitivity. Paclitaxel treatment regimens commonly used to model chemotherapy-induced neuropathic pain in rats are not sufficient to depress ICSS.

show abstract

Section: Introductionmentioning

confidence: 99%

Lack of paclitaxel effects on intracranial self-stimulation in male and female rats: comparison to mechanical sensitivity

Legakis

Bigbee

Negus

2018

Behavioural Pharmacology

View full text Add to dashboard Cite

show abstract

“…It exerts a significant effect on a variety of solid tumors, especially breast cancer, advanced ovarian cancer, non-small cell lung cancer, and Kaposi's sarcoma. [89][90][91] It has also been successfully used in nasopharyngeal cancer 92,93 and gastric cancer. 94,95 This study confirmed that paclitaxel inhibits the deacetylation of microtubules by EBV-miR-BART12, suggesting that paclitaxel may exert a significant inhibitory effect on nasopharyngeal and gastric cancer cells highly expressing EBV-miR-BART12.…”

Section: Discussionmentioning

confidence: 99%

EBV‐miR‐BART12 accelerates migration and invasion in EBV‐associated cancer cells by targeting tubulin polymerization‐promoting protein 1

Wang

Fang

et al. 2020

FASEB j.

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) infection leads to cancers with an epithelial origin, such as nasopharyngeal cancer and gastric cancer, as well as multiple blood cell-based malignant tumors, such as lymphoma. Interestingly, EBV is also the first virus found to carry genes encoding miRNAs. EBV encodes 25 types of pre-miRNAs which are finally processed into 44 mature miRNAs. Most EBV-encoded miRNAs were found to be involved in the occurrence and development of EBV-related tumors. However, the function of EBV-miR-BART12 remains unclear. The findings of the current study revealed that EBV-miR-BART12 binds to the 3'UTR region of Tubulin Polymerization-Promoting Protein 1 (TPPP1) mRNA and downregulates TPPP1, thereby promoting the invasion and migration of EBV-related cancers, such as nasopharyngeal cancer and gastric cancer. The mechanism underlying this process was found to be the inhibition of TPPP1 by EBV-miRNA-BART12, which, in turn, inhibits the acetylation of α-tubulin, and promotes the dynamic assembly of microtubules, remodels the cytoskeleton, and enhances the acetylation of β-catenin. β-catenin activates epithelial to mesenchymal transition (EMT). These two processes synergistically promote the invasion and metastasis of tumor cells. To the best of our knowledge, this is the first study to reveal the role of EBV-miRNA-BART12 in the development of EBV-related tumors as well as the mechanism underlying this process, and suggests potential targets and strategies for the treatment of EBV-related tumors.

show abstract

“…However, bone marrow metastasis from NPC is rare, and the prognosis for these patients is exceedingly poor (8)(9)(10). Due to the severe complications associated with bone marrow metastasis, patients are typically ineligible for standard first-line regimens.…”

Section: Introductionmentioning

confidence: 99%

Case report: Immunotherapy-based combination therapy achieving complete remission and prolonged survival in nasopharyngeal carcinoma with extensive bone marrow metastasis

Wang,

Yuan,

Zhang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Nasopharyngeal carcinoma with bone marrow metastasis presents a rare and challenging clinical scenario associated with exceedingly poor prognosis. While standard treatment regimens offer limited efficacy and tolerability in such cases, individualized approaches are increasingly necessary. We present the case of a 64-year-old male diagnosed with recurrent nonkeratinizing undifferentiated nasopharyngeal carcinoma with extensive bone marrow metastasis (rTxN0M1). Treatment was initiated with immunotherapy-based combination therapy, consisting of pembrolizumab and low-dose cisplatin, which resulted in an initial response. Subsequently, there was a transition to standard-dose nab-paclitaxel-cisplatin chemotherapy in combination with pembrolizumab, followed by maintenance therapy with pembrolizumab plus fruquintinib. The patient achieved a sustained response with renormalization of tumor markers, imaging findings, and bone biopsies, resulting in complete remission. This case highlights the successful management of nasopharyngeal carcinoma with extensive bone marrow metastasis through an individualized treatment approach incorporating immunotherapy.

show abstract

Nasopharyngeal Carcinoma with Bone Marrow Metastasis: Positive Response to Weekly Paclitaxel Chemotherapy

Cited by 6 publications

References 32 publications

Lack of paclitaxel effects on intracranial self-stimulation in male and female rats: comparison to mechanical sensitivity

Lack of paclitaxel effects on intracranial self-stimulation in male and female rats: comparison to mechanical sensitivity

EBV‐miR‐BART12 accelerates migration and invasion in EBV‐associated cancer cells by targeting tubulin polymerization‐promoting protein 1

Case report: Immunotherapy-based combination therapy achieving complete remission and prolonged survival in nasopharyngeal carcinoma with extensive bone marrow metastasis

Contact Info

Product

Resources

About